Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AnnJi-Pharmaceutical

More Like This

PR Newswire associated0

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Keymed Biosciences Announces 2023 Annual Results and Business Updates